Prestige Consumer Healthcare Inc.
PBH- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001295947
No open-market purchases or sales by Prestige Consumer Healthcare Inc. insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.54B in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q1 2025
Institutional positions in Prestige Consumer Healthcare Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 358
- +25 vs. Q4 2024
- Shares held
- 51.7M
- −578.7K (−1.1%) vs. Q4 2024
- Total value
- $4.44B
- +$361.1M (+8.8%) vs. Q4 2024
- New holders
- 47
- 108 more added
- Sold out
- 22
- 154 more reduced
4 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PBH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 319 | $2.54B |
| Q1 2026 | 354 | $3.08B |
| Q4 2025 | 354 | $3.18B |
| Q3 2025 | 356 | $3.17B |
| Q2 2025 | 377 | $4.16B |
| Q1 2025 | 358 | $4.44B |
| Q4 2024 | 337 | $4.10B |
| Q3 2024 | 327 | $3.68B |
| Q2 2024 | 305 | $3.51B |
| Q1 2024 | 312 | $3.72B |
| Q4 2023 | 288 | $3.13B |
| Q3 2023 | 280 | $2.91B |
| Q2 2023 | 278 | $2.97B |
| Q1 2023 | 283 | $3.16B |
| Q4 2022 | 288 | $3.13B |
| Q3 2022 | 276 | $2.49B |
| Q2 2022 | 285 | $2.98B |
| Q1 2022 | 286 | $2.67B |
| Q4 2021 | 271 | $3.07B |
| Q3 2021 | 248 | $2.85B |
| Q2 2021 | 227 | $2.71B |
| Q1 2021 | 240 | $2.32B |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Prestige Consumer Healthcare Inc.; share changes are against Q4 2024.